Quantcast

Industry news that matters to you.  Learn more

Human Longevity, Inc. Signs Collaborative Agreement with King’s College London to Access TwinsUK Registry

Reading time: 2 – 3 minutes

Human Longevity, Inc. (HLI), a biological data-driven human health technology and cell therapy company, recently announced a collaborative agreement with King’s College London to access their TwinsUK Registry.

Tim Spector, MD, Professor of Genetic Epidemiology, King’s College London, and Director of the Department of Twin Research and Genetic Epidemiology at St. Thomas’ Hospital, London started the registry in 1993. HLI and Dr. Spector will collaborate directly as part of the agreement. With more than 11,000 twin individuals, the Registry is one of the most comprehensive collections of genome and microbiome samples paired with phenotype information in the world.

HLI will conduct whole genome and microbiome sequencing on up to 2,000 individuals, along with metabolomic analysis on up to 6,000 longitudinal samples in TwinsUK. HLI is working with the company Metabolon to perform the metabolite profiling.

HLI is currently sequencing and analyzing 2,000 genomes per month using Illumina’s HiSeq X Ten sequencing machines. The combined high quality, comprehensive data will continue to enrich the HLI Database and HLI Knowledge Base, which includes the company’s proprietary informatics analysis and data interpretation and integration. The Database and Knowledge Base form the core of HLI’s business. The company is pursuing agreements with a variety of customers including pharmaceutical and biotech companies, academic health systems, governments and insurers.

“The TwinsUK Registry is one of the largest and best characterized databases of individuals in the world,” said J. Craig Venter, PhD, HLI’s Co-founder, Chairman, and Chief Executive Officer. “Having access to the clinical phenotype information collected by Dr. Spector and his team will greatly enhance our Database and Knowledge Base, and will enable the teams to collaborate on identifying correlations between phenotypes and genetic predisposition to disease and health.”

Dr. Spector commented, “Combining our detailed health data collected for more than 21 years on the twins with new metagenomics of gut microbes and the exciting technology of metabolomics in longitudinal samples is an amazing opportunity. The next generation sequencing and analysis expertise of HLI, plus the unique data and design of the twin study, provides the perfect platform to unlock the clues to aging-related diseases and personalized medicine.”

Source: Human Longevity